THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 122 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $228,902 | -16.6% | 26,524 | 0.0% | 0.00% | – |
| Q2 2023 | $274,523 | -2.5% | 26,524 | +2.2% | 0.00% | – |
| Q1 2023 | $281,547 | -3.3% | 25,949 | 0.0% | 0.00% | – |
| Q4 2022 | $291,148 | +10.7% | 25,949 | 0.0% | 0.00% | – |
| Q3 2022 | $263,123 | +18.5% | 25,949 | +5.7% | 0.00% | -100.0% |
| Q2 2022 | $222,000 | -43.2% | 24,541 | -40.1% | 0.00% | 0.0% |
| Q1 2022 | $391,000 | -14.1% | 40,936 | -0.6% | 0.00% | 0.0% |
| Q4 2021 | $455,000 | +189.8% | 41,198 | +94.1% | 0.00% | – |
| Q3 2021 | $157,000 | -48.5% | 21,229 | +1.1% | 0.00% | -100.0% |
| Q2 2021 | $305,000 | -30.8% | 21,001 | -2.8% | 0.00% | 0.0% |
| Q1 2021 | $441,000 | +24.2% | 21,615 | +8.0% | 0.00% | 0.0% |
| Q4 2020 | $355,000 | +41.4% | 20,005 | +18.1% | 0.00% | 0.0% |
| Q3 2020 | $251,000 | -29.5% | 16,943 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $356,000 | -35.5% | 16,943 | -29.1% | 0.00% | 0.0% |
| Q1 2020 | $552,000 | +0.4% | 23,885 | +12.5% | 0.00% | 0.0% |
| Q4 2019 | $550,000 | +49.9% | 21,232 | +12.8% | 0.00% | 0.0% |
| Q3 2019 | $367,000 | +19.5% | 18,830 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $307,000 | -24.6% | 18,830 | +5.0% | 0.00% | 0.0% |
| Q1 2019 | $407,000 | -14.1% | 17,934 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $474,000 | -17.4% | 18,517 | +5.4% | 0.00% | 0.0% |
| Q3 2018 | $574,000 | +43.9% | 17,575 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $399,000 | -13.3% | 17,575 | -7.3% | 0.00% | 0.0% |
| Q1 2018 | $460,000 | -13.0% | 18,950 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $529,000 | -18.5% | 18,950 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $649,000 | -14.0% | 18,950 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $755,000 | +37.8% | 18,950 | +27.3% | 0.00% | +100.0% |
| Q1 2017 | $548,000 | +15.6% | 14,883 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $474,000 | -12.1% | 14,883 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $539,000 | +59.5% | 14,883 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $338,000 | +44.4% | 14,883 | +19.8% | 0.00% | 0.0% |
| Q1 2016 | $234,000 | +14.7% | 12,422 | 0.0% | 0.00% | – |
| Q4 2015 | $204,000 | +48.9% | 12,422 | 0.0% | 0.00% | – |
| Q3 2015 | $137,000 | -15.4% | 12,422 | 0.0% | 0.00% | – |
| Q2 2015 | $162,000 | -25.0% | 12,422 | 0.0% | 0.00% | – |
| Q1 2015 | $216,000 | +16.8% | 12,422 | 0.0% | 0.00% | – |
| Q4 2014 | $185,000 | -35.3% | 12,422 | 0.0% | 0.00% | -100.0% |
| Q3 2014 | $286,000 | -28.3% | 12,422 | -0.7% | 0.00% | 0.0% |
| Q2 2014 | $399,000 | – | 12,504 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |